(DESTINY-BTC01) A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
首席研究员（PI）
ClinicalTrials.gov ID
关键资格
协议 ＃
赞助
